镰状细胞病的疾病调整疗法--概述。

IF 1.1 4区 医学 Q3 PEDIATRICS Pediatric Annals Pub Date : 2024-02-01 DOI:10.3928/19382359-20231205-05
Radhika Peddinti
{"title":"镰状细胞病的疾病调整疗法--概述。","authors":"Radhika Peddinti","doi":"10.3928/19382359-20231205-05","DOIUrl":null,"url":null,"abstract":"<p><p>Sickle cell disease refers to a group of inherited blood disorders in which hemoglobin polymerization leads to hemolysis and vaso-occlusion. This causes a myriad of complications during a patient's life span, ranging from anemia, infections, and acute and chronic pain to stroke and multiorgan dysfunction. Although there have been dramatic improvements in childhood survival thanks to improved supportive care with penicillin prophylaxis, immunizations, and improved transfusion practices, there was a dearth of disease-modifying therapies, with hydroxyurea being the only medication for >20 years. Here, we discuss the newer therapies for sickle cell disease that have emerged in recent years. <b>[<i>Pediatr Ann</i>. 2024;53(2):e52-e55.]</b>.</p>","PeriodicalId":54633,"journal":{"name":"Pediatric Annals","volume":"53 2","pages":"e52-e55"},"PeriodicalIF":1.1000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Disease-Modifying Therapies for Sickle Cell Disease-An Overview.\",\"authors\":\"Radhika Peddinti\",\"doi\":\"10.3928/19382359-20231205-05\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sickle cell disease refers to a group of inherited blood disorders in which hemoglobin polymerization leads to hemolysis and vaso-occlusion. This causes a myriad of complications during a patient's life span, ranging from anemia, infections, and acute and chronic pain to stroke and multiorgan dysfunction. Although there have been dramatic improvements in childhood survival thanks to improved supportive care with penicillin prophylaxis, immunizations, and improved transfusion practices, there was a dearth of disease-modifying therapies, with hydroxyurea being the only medication for >20 years. Here, we discuss the newer therapies for sickle cell disease that have emerged in recent years. <b>[<i>Pediatr Ann</i>. 2024;53(2):e52-e55.]</b>.</p>\",\"PeriodicalId\":54633,\"journal\":{\"name\":\"Pediatric Annals\",\"volume\":\"53 2\",\"pages\":\"e52-e55\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Annals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/19382359-20231205-05\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Annals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/19382359-20231205-05","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

摘要

镰状细胞病是一组遗传性血液疾病,血红蛋白聚合会导致溶血和血管闭塞。镰状细胞病会在患者的一生中引起各种并发症,包括贫血、感染、急性和慢性疼痛、中风和多器官功能障碍。虽然由于青霉素预防、免疫接种和输血实践等支持性护理的改善,儿童患者的存活率有了显著提高,但改变病情的疗法却十分匮乏,羟基脲是 20 多年来唯一的药物。在此,我们将讨论近年来新出现的镰状细胞病疗法。[2024;53(2):e52-e55.].
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Disease-Modifying Therapies for Sickle Cell Disease-An Overview.

Sickle cell disease refers to a group of inherited blood disorders in which hemoglobin polymerization leads to hemolysis and vaso-occlusion. This causes a myriad of complications during a patient's life span, ranging from anemia, infections, and acute and chronic pain to stroke and multiorgan dysfunction. Although there have been dramatic improvements in childhood survival thanks to improved supportive care with penicillin prophylaxis, immunizations, and improved transfusion practices, there was a dearth of disease-modifying therapies, with hydroxyurea being the only medication for >20 years. Here, we discuss the newer therapies for sickle cell disease that have emerged in recent years. [Pediatr Ann. 2024;53(2):e52-e55.].

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pediatric Annals
Pediatric Annals 医学-小儿科
CiteScore
1.80
自引率
0.00%
发文量
104
审稿时长
2 months
期刊介绍: Published for more than 40 years, Pediatric Annals is an online-only, monthly medical review journal dedicated to providing pediatricians and other clinicians with the latest practical information on the diagnosis and treatment of pediatric diseases and disorders. Begin to explore the Journal and all of its great benefits such as: -Single-topic summary reviews of important trends in pediatric medicine -Access to current articles, as well as several years of archived content -Columns including Healthy Baby/Healthy Child and Case Challenges
期刊最新文献
From Simulation to Bedside: The Journey to Provide Equitable Patient Care. Gamification, Serious Games, and Simulation in Health Professions Education. Give Your Toys a Broader Story: Simulation for Advocacy, Community Education, and Empowerment. Neonatal Bacterial Meningitis: What Have We Learned From the Last Decade? Practical Strategies for Promoting Healthier Lifestyles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1